拜复乐治疗急性重症型胆管炎15例疗效评价  

Clinical evaluation of Moxifloxacina in treatment of patients with acute cholangitis of severe type 15 cases

作　　者：梁声庆 

机构地区：[1]潢川县人民医院,河南潢川465100

出　　处：《医药论坛杂志》2011年第21期79-81,共3页Journal of Medical Forum

摘　　要：目的观察拜复乐治疗重度胆管炎的疗效。方法重度胆管炎患者32例,治疗组15例采用拜复乐治疗,对照组17例采用头孢哌酮/舒巴坦治疗,疗程均为7～15d,整个治疗过程辅助治疗相同。结果治疗组有效率为92%,对照组有效率为93%。治疗组不良反应率5%,对照组不良反应率3%,两组比较无统计学差异(P>0.05)。结论拜复乐治疗重度胆管炎临床疗效良好,可以在必要时作为较理想的临床选用。Objective To evaluate the efficacy of moxifloxacina in treatment of acute cholangitis of severe type（ACST）.Methods Thirty-two patients with ACST have been studied.In treatment group,15 patients were given moxifloxacina therapy,the control group of 17 patients were trentment with cefoperazone / sulbactam therapy,a course 7 to 15 days,the same adjuvant therapy throughout the treatment process.Results The effective rate in treatment group was 92% and the control group was 93%.Treatment group adverse reactions rate was 5%,and the control group was 3%,and there were no obviousl difference between two groups（P〉0.05）.Conclusions Moxifloxacina is as effective as sulbactam/ ceto pazone in treatment of ACST.

关 键 词：拜复乐 急性重症胆管炎 疗效评价 

分 类 号：R657.45[医药卫生—外科学]